Pierre Verger1,2,3, Sébastien Cortaredona4,5,6, Marie Tournier7,8,9, Dominique Rey1,2,3, Marc-Karim Bendiane1,2,3, Patrick Peretti-Watel1,2,3, Hélène Verdoux7,8,9. 1. INSERM, UMR912 (SESSTIM), Marseille, France. 2. Aix Marseille Université, UMR_S912, IRD, Marseille, France. 3. ORS PACA, Observatoire Régional de la Santé Provence-Alpes-Côte d'Azur, Marseille, France. 4. INSERM, UMR912 (SESSTIM), Marseille, France. sebastien.cortaredona@inserm.fr. 5. Aix Marseille Université, UMR_S912, IRD, Marseille, France. sebastien.cortaredona@inserm.fr. 6. ORS PACA, Observatoire Régional de la Santé Provence-Alpes-Côte d'Azur, Marseille, France. sebastien.cortaredona@inserm.fr. 7. Université de Bordeaux, U657, Bordeaux, France. 8. INSERM, U657, Bordeaux, France. 9. Centre Hospitalier Charles Perrens, Bordeaux, France.
Abstract
PURPOSE: To compare annual and monthly prevalence of psychotropic drug (PD) dispensing and the number and duration of psychotropic treatment episodes among people with and without cancer over a 2-year follow-up. METHODS: We studied the following two cohorts of adult patients affiliated with the National Health Insurance Fund (NHIF): cancer patients followed for 2 years after diagnosis and individuals without cancer matched to cancer patients. Using information about anxiolytic, hypnotic, antidepressant, and antipsychotic dispensing in community pharmacies, we applied conditional log-binomial regressions to estimate adjusted relative risks for monthly dispensing of PDs. RESULTS: Annual prevalence of PD dispensing-all categories included-among cancer patients was significantly higher for almost all the categories we studied than among individuals without cancer. Monthly prevalence of anxiolytic/hypnotic dispensing started to rise several months before diagnosis and peaked immediately after. Among patients with cancer and their matched controls, treatment duration exceeded 1 month for hypnotics in 40 and 35 %, respectively (p < 0.01), and 3 months for anxiolytics in 23 and 23 % (p = 0.8); it was less than 6 months for antidepressants in 76 and 75 % (p = 0.5). CONCLUSIONS: Prevalence of psychotropic treatment was higher among cancer patients than among persons without cancer. Psychotropic treatment duration was not in line with recommendations for significant fractions of cancer patients or their controls. IMPLICATIONS FOR CANCER SURVIVORS: Training of health professionals involved in cancer supportive care should be reinforced and specific guidelines developed to help them address psychological distress of cancer survivors.
PURPOSE: To compare annual and monthly prevalence of psychotropic drug (PD) dispensing and the number and duration of psychotropic treatment episodes among people with and without cancer over a 2-year follow-up. METHODS: We studied the following two cohorts of adult patients affiliated with the National Health Insurance Fund (NHIF): cancerpatients followed for 2 years after diagnosis and individuals without cancer matched to cancerpatients. Using information about anxiolytic, hypnotic, antidepressant, and antipsychotic dispensing in community pharmacies, we applied conditional log-binomial regressions to estimate adjusted relative risks for monthly dispensing of PDs. RESULTS: Annual prevalence of PD dispensing-all categories included-among cancerpatients was significantly higher for almost all the categories we studied than among individuals without cancer. Monthly prevalence of anxiolytic/hypnotic dispensing started to rise several months before diagnosis and peaked immediately after. Among patients with cancer and their matched controls, treatment duration exceeded 1 month for hypnotics in 40 and 35 %, respectively (p < 0.01), and 3 months for anxiolytics in 23 and 23 % (p = 0.8); it was less than 6 months for antidepressants in 76 and 75 % (p = 0.5). CONCLUSIONS: Prevalence of psychotropic treatment was higher among cancerpatients than among persons without cancer. Psychotropic treatment duration was not in line with recommendations for significant fractions of cancerpatients or their controls. IMPLICATIONS FOR CANCER SURVIVORS: Training of health professionals involved in cancer supportive care should be reinforced and specific guidelines developed to help them address psychological distress of cancer survivors.
Entities:
Keywords:
Cancer; Health insurance reimbursement; Oncology; Psychotropic drugs; Quality of health care; Survivors
Authors: M Jardin; A Bocquier; S Cortaredona; S Nauleau; C Millon; S Savard-Chambard; V Allaria-Lapierre; V Sciortino; G Bouvenot; P Verger Journal: Rev Epidemiol Sante Publique Date: 2012-03-13 Impact factor: 1.019
Authors: Pepijn Brocken; Judith B Prins; P N Richard Dekhuijzen; Henricus F M van der Heijden Journal: Psychooncology Date: 2012-01 Impact factor: 3.894
Authors: L R Derogatis; M Feldstein; G Morrow; A Schmale; M Schmitt; C Gates; B Murawski; J Holland; D Penman; N Melisaratos; A J Enelow; L M Adler Journal: Cancer Date: 1979-11 Impact factor: 6.860
Authors: A Brédart; J-L Kop; A-C Griesser; C Fiszer; K Zaman; B Panes-Ruedin; W Jeanneret; J-F Delaloye; S Zimmers; V Berthet; S Dolbeault Journal: Ann Oncol Date: 2013-04-07 Impact factor: 32.976
Authors: Karen Barnett; Stewart W Mercer; Michael Norbury; Graham Watt; Sally Wyke; Bruce Guthrie Journal: Lancet Date: 2012-05-10 Impact factor: 79.321
Authors: Jacob C Cogan; Rohit R Raghunathan; Melissa P Beauchemin; Melissa K Accordino; Elena B Elkin; Alexander Melamed; Jason D Wright; Dawn L Hershman Journal: Breast Cancer Res Treat Date: 2021-06-04 Impact factor: 4.872
Authors: B Davin-Casalena; M Jardin; H Guerrera; H Tréhard; D Lapalus; C Ménager; S Nauleau; V Cassaro; P Verger; V Guagliardo Journal: Rev Epidemiol Sante Publique Date: 2021-04-27 Impact factor: 1.019
Authors: B Davin-Casalena; M Jardin; H Guerrera; J Mabille; H Tréhard; D Lapalus; C Ménager; S Nauleau; V Cassaro; P Verger; V Guagliardo Journal: Rev Epidemiol Sante Publique Date: 2021-08-10 Impact factor: 1.019